The HIV Vaccine Trials Network (HPTN) and HIV Prevention Trials network are collaborating in doing a research/study to assess whether the anti-HIV antibody called VRC01 made from the laboratory may be able to prevent HIV infection in people who are most at risk of contracting HIV.

Approximately 1,500 women will take part in the AMP study at multiple research sites in Sub- Saharan Africa. In Malawi, this study will be conducted at Queen Elizabeth Central Hospital and Kamuzu Central Hospital.
MASYAP was one of a few key Malawi representatives at stakeholder consultation meeting of the study. The two days meeting was held on the 11th and 12th of August at South Africa, Cape Town.
The anticipated outcome for the meeting was a dialogue, mutual understanding and partnership for the study.
Based on the presentations made by representatives about the programs they are running in their communities/organizations, MASYAP proves to be ahead of many NGOS and in line with the HPTN and HVTN goals and strategies used to fight against the epidemic of HIV.

MASYAP will raise awareness of this trial amongst it’s 1500 strong membership in Blantyre and surrounding district with some MASYAP members becoming trial volunteers.

MASYAP part of community stakeholder process to trial new HIV prevention antibodies